MedTrace Logo

Vascular Effect of CIMICIFUGA RACEMOSA

NCT03786809 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-08-14

No results posted yet for this study

Summary

Postmenopausal women with vascular symptoms will use Cimifuga Racemosa or Placebo and the effects will be evaluated using Flow-Mediated Dilatation of the brachial artery.

Conditions

  • Postmenopausal Symptoms

Interventions

DRUG

Cimifuga Racemosa

Experimental group will use 160mg of Cimifuga Racemosa for 28 days

DRUG

Placebo

patients of the placebo group will use placebo once a day for 28 days

Sponsors & Collaborators

  • Federal University of Minas Gerais

    lead OTHER

Principal Investigators

  • Selmo Geber, MD PhD · Universidde Federal de Minas Gerais

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2019-04-30
Completion
2019-05-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03786809 on ClinicalTrials.gov